Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Oncol Pharm Pract ; 29(8): 1853-1861, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36579812

RESUMO

INTRODUCTION: Administering pegfilgrastim on the same day as chemotherapy can improve patient satisfaction through convenience and may increase the utilization of cost-effective biosimilars compared to next-day administration, but the effect on clinical outcomes with commonly used breast cancer regimens is unclear. METHODS: This multi-site, retrospective cohort study included breast cancer patients age 18 years or older who received dose-dense doxorubicin and cyclophosphamide (ddAC) and pegfilgrastim between 1 June 2016 and 31 May 2020. Pegfilgrastim was given on the same day as chemotherapy at one site and the day after chemotherapy at the other two sites. The primary endpoint compared the incidence of febrile neutropenia associated with pegfilgrastim administration timing. RESULTS: A total of 360 patients were reviewed (146 same-day administration and 214 next-day administration). In the same-day group 36 patients (24.6%) developed FN compared to 25 patients (11.7%) in the next-day group (p = 0.002). Same-day administration also significantly increased the incidences of additional acute care visits (11.6% vs 2.8%, p = 0.0016), grade ≥ 3 neutropenia (38.4% vs 13.6%, p < 0.0001), chemotherapy dose reductions (21.2% vs 6.1%, p < 0.0001), and antibiotic use (26.7% vs 12.6%, p = 0.001). Same-day administration did not significantly increase the rate of hospitalization (15% vs 11.2%, p = 0.36) and delay of next chemotherapy cycle by ≥1 day (8.2% vs 6.1%, p = 0.57) due to neutropenic complications. CONCLUSIONS: Administering pegfilgrastim on the same day as ddAC led to a significant increase in neutropenic complications. This study confirms the need to administer pegfilgrastim the day after chemotherapy in breast cancer patients receiving ddAC.


Assuntos
Neoplasias da Mama , Neutropenia Febril Induzida por Quimioterapia , Adolescente , Feminino , Humanos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Medicamentos Biossimilares/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/complicações , Neutropenia Febril Induzida por Quimioterapia/epidemiologia , Neutropenia Febril Induzida por Quimioterapia/prevenção & controle , Neutropenia Febril Induzida por Quimioterapia/tratamento farmacológico , Ciclofosfamida , Doxorrubicina/uso terapêutico , Filgrastim/uso terapêutico , Polietilenoglicóis , Estudos Retrospectivos , Adulto
3.
J Oncol Pharm Pract ; 26(1): 23-28, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30854925

RESUMO

INTRODUCTION: Filgrastim, a granulocyte colony-stimulating factor, is commonly used in autologous hematopoietic stem cell transplants (HSCTs) to assist with peripheral blood progenitor cell (PBPC) collection and to support stem cell engraftment. In the United States, tbo-filgrastim is approved under its own Biologic License Application and is limited to a single indication excluding the HSCT population. METHODS: Approximately one year after a system-wide formulary change to tbo-filgrastim for all on- and off-label indications, our institution conducted an IRB-approved retrospective comparison of tbo-filgrastim to filgrastim in the autologous HSCT setting. The study included 71 patients who received an autologous HSCT from 1 January 2013 to 31 December 2016 with a documented administration of tbo-filgrastim or filgrastim. RESULTS: There were no statistically significant differences noted on CD34 + counts during stem cell mobilization, neutrophil engraftment, infection rates during the engraftment phase, nor duration of hospitalization during the engraftment phase. More patients in the tbo-filgrastim group received plerixafor per protocol resulting in more patients meeting their PBPC collection goal in one day with fewer collection days overall, a result potentially confounded by institutional protocol changes. Utilizing tbo-filgrastim offered an average cost savings per patient of $2664.26 ($1907.33 for PBPC mobilization and $756.93 for stem cell engraftment) when comparing dollars spent on granulocyte colony-stimulating factor products only. CONCLUSION: Tbo-filgrastim demonstrates comparable efficacy with a cost savings benefit compared to filgrastim for autologous PBPC mobilization and stem cell engraftment.


Assuntos
Filgrastim/uso terapêutico , Fármacos Hematológicos/uso terapêutico , Mobilização de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco Hematopoéticas/métodos , Idoso , Feminino , Filgrastim/economia , Rejeição de Enxerto/economia , Rejeição de Enxerto/prevenção & controle , Fármacos Hematológicos/economia , Mobilização de Células-Tronco Hematopoéticas/economia , Transplante de Células-Tronco Hematopoéticas/economia , Hospitalização/economia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Transplante Autólogo/economia , Transplante Autólogo/métodos
4.
J Oncol Pharm Pract ; 25(4): 806-812, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29486638

RESUMO

BACKGROUND: Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists. PURPOSE: The purpose of this study was to assess overall adherence to guideline recommendations for anticoagulation therapy with lenalidomide and pomalidomide in multiple myeloma patients. METHODS: This retrospective study at an ambulatory oncology clinic utilized chart reviews from the calendar years 2013-2016. The primary endpoint was prescription of appropriate anticoagulation upon initiation of therapy based on a list of predetermined risk factors. Secondary endpoints included incidence of deep venous thromboembolism, pulmonary embolism, myocardial infarction, stroke, and major bleed; initial anticoagulant prescribed; and whether or not anticoagulation was prescribed for another disease state. RESULTS: A total of 130 patients met inclusion criteria: 70.8% (n = 92) and 29.2% (n = 38) were prescribed lenalidomide and pomalidomide, respectively. A total risk score of two was most common (n = 54, 41.5%). Aspirin 81 mg oral tablet was prescribed most often (n = 53, 40.8%), followed by no anticoagulation (n = 30, 23.1%). Overall, 27 patients (20.8%) were prescribed anticoagulation in accordance with National Comprehensive Cancer Network guidelines. Incidence of deep venous thromboembolism was the most common adverse event (n = 4, 3.1%), followed by major bleed (n = 1, 0.8%). No reports of pulmonary embolism, myocardial infarction, or stroke were documented. CONCLUSIONS: Overall, a disparity exists between appropriate prescribing of prophylactic anticoagulation and current practice guidelines. However, documentation of thromboembolic events was lower than recorded in previously published literature.


Assuntos
Anticoagulantes/uso terapêutico , Lenalidomida/uso terapêutico , Mieloma Múltiplo/tratamento farmacológico , Talidomida/análogos & derivados , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar/epidemiologia , Embolia Pulmonar/prevenção & controle , Estudos Retrospectivos , Talidomida/uso terapêutico , Tromboembolia Venosa/epidemiologia , Tromboembolia Venosa/prevenção & controle
5.
Aviat Space Environ Med ; 78(4 Suppl): A14-25, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17511295

RESUMO

INTRODUCTION: While the physiologic effects of space travel are documented in healthy individuals, little is known about its impact on medically ill or injured persons. In this study, hemorrhagic shock in primates was used to model a potentially common pathophysiologic condition during exposure to gravitational forces simulating return from Earth orbit. This experiment did not model the effects of cardiovascular deconditioning that normally occur during spaceflight. METHODS: Using invasive hemodynamic monitoring, serial cardiovascular and laboratory parameters in baboons (Papio papio) were studied. Subjects were centrifuged at either a low +Gx (3.3 G maximum) or high +Gx (7.8 G maximum) acceleration reentry profile before and after being subjected to either class II (20% volume loss) or class IV (40% volume loss) hemorrhagic shock. RESULTS: Significant alterations in cardiovascular and laboratory parameters occurred during shock and exposure to high and low +Gx acceleration. Shock classification was the primary determinant of change in cardiovascular function. During the experimental protocol, 31 of 32 animals survived (97% survival). After a 1-wk post-protocol observation period, 28 of 32 subjects survived (88% survival). CONCLUSIONS: This preliminary study presents data that suggest that the emergent return of a medically compromised individual without resuscitation may be potentially survivable. However, medical stabilization with volume resuscitation, supplemental oxygen, and noninvasive monitoring would likely optimize clinical outcomes in the event of significant hemorrhagic shock states necessitating emergent deorbit.


Assuntos
Medicina Aeroespacial , Sistema Cardiovascular , Centrifugação/efeitos adversos , Simulação por Computador , Hipergravidade/efeitos adversos , Papio/fisiologia , Choque Hemorrágico/etiologia , Aceleração/efeitos adversos , Animais , Masculino , Modelos Animais , Fatores de Risco , Choque Hemorrágico/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA